Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Targovax (Norway)
h-index: 9
Total citations: 399
Total papers: 31
Homepage:
http://www.targovax.com/
Recent papers from Targovax (Norway)
A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer
Heliyon · 2024
Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models
Molecular Therapy — Oncolytics · 2023
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Clinical Cancer Research · 2022
Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data
European Journal of Cancer · 2022
Best practice standards for circular RNA research
Nature Methods · 2022
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial
British Journal of Cancer · 2020
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor
Journal of Medical Virology · 2020
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
Journal of Medical Virology · 2019
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks
International Journal of Molecular Sciences · 2019
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
OncoImmunology · 2018
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
Journal of Medical Virology · 2018